| scholarly article | Q13442814 |
| P50 | author | Emmanuel Roilides | Q61097982 |
| P2093 | author name string | Maria Simitsopoulou | |
| Aspasia Katragkou | |||
| Athanasios Chatzimoschou | |||
| Chaido Tsantali | |||
| Eudoxia Diza-Mataftsi | |||
| Maria Dalakiouridou | |||
| P2860 | cites work | Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. | Q30452376 |
| Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance | Q30701532 | ||
| Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins | Q31058690 | ||
| In vitro activity of caspofungin against Candida albicans biofilms. | Q31114513 | ||
| Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-t etrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast [...] | Q33667850 | ||
| Evaluation of endpoints for antifungal susceptibility determinations with LY303366. | Q33693384 | ||
| Candida biofilms and their susceptibility to antifungal agents | Q33766274 | ||
| Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms | Q33982871 | ||
| Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus | Q34509692 | ||
| Candida biofilm resistance | Q35943395 | ||
| Candida biofilm: a well-designed protected environment | Q36190737 | ||
| Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations | Q39954432 | ||
| Intravascular-catheter-related infections | Q41731164 | ||
| Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences | Q42747700 | ||
| Antifungal resistance of candidal biofilms formed on denture acrylic in vitro | Q43622404 | ||
| Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms | Q46616041 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biofilm | Q467410 |
| Candida parapsilosis | Q144068 | ||
| Candida albicans | Q310443 | ||
| P304 | page(s) | 357-360 | |
| P577 | publication date | 2007-10-15 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms | |
| P478 | volume | 52 |
| Q47135320 | A rare case of Candida parapsilosis osteomyelitis: a literature review and proposed treatment algorithm |
| Q34932922 | Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells |
| Q46600218 | Activity of anidulafungin against Candida biofilms |
| Q33451098 | Activity of micafungin against Candida biofilms |
| Q37624719 | Anidulafungin, a new echinocandin: in vitro activity |
| Q37854724 | Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections? |
| Q51738042 | Anti-Candida activity of antidepressants sertraline and fluoxetine: effect upon pre-formed biofilms. |
| Q90734758 | Antifungal Drugs for Invasive Candida Infections (ICI) in Neonates: Future Perspectives |
| Q27025682 | Antifungal lock therapy |
| Q37906758 | Antifungal susceptibility of Candida albicans in biofilms |
| Q89912181 | Antifungal susceptibility pattern and biofilm-related genes expression in planktonic and biofilm cells of Candida parapsilosis species complex |
| Q40606434 | Azole-resistant Candida albicans prosthetic joint infection treated with prolonged administration of anidulafungin and two-stage exchange with implant of a mega-prosthesis. |
| Q36933366 | Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species |
| Q37392907 | Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates |
| Q36283867 | Biofilm formation of the black yeast-like fungus Exophiala dermatitidis and its susceptibility to antiinfective agents |
| Q44925984 | Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. |
| Q48163282 | Candida Species Biofilms' Antifungal Resistance. |
| Q28533912 | Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis |
| Q41699308 | Candida parapsilosis osteomyelitis |
| Q34852747 | Candida parapsilosis, an emerging fungal pathogen |
| Q37613000 | Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility |
| Q91983100 | Candida parapsilosis: from Genes to the Bedside |
| Q37624702 | Candidaemia in patients with an inserted medical device. |
| Q34058104 | Caspofungin at catheter lock concentrations eradicates mature biofilms of Candida lusitaniae and Candida guilliermondii |
| Q51041040 | Characterization of Candida parapsilosis complex strains isolated from invasive fungal infections. |
| Q37624704 | Clinical aspects of invasive candidiasis: endocarditis and other localized infections |
| Q42751895 | Clinical experience of anidulafungin for the treatment of patients with documented candidemia. |
| Q52333026 | Conservation and Divergence in the Candida Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control. |
| Q38149163 | Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients |
| Q40900363 | Differential effects of antifungal agents on expression of genes related to formation of Candida albicans biofilms |
| Q37892184 | Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections |
| Q37974743 | Echinocandins: are they all the same? |
| Q40625328 | Efficacy of anidulafungin in the treatment of experimental Candida parapsilosis catheter infection using an antifungal-lock technique. |
| Q41843284 | Elevated chitin content reduces the susceptibility of Candida species to caspofungin |
| Q36785910 | Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin. |
| Q35821475 | Fungal biofilm resistance |
| Q41848811 | Fungal echinocandin resistance. |
| Q39065051 | Genetic Drivers of Multidrug Resistance in Candida glabrata |
| Q42178504 | Growth Inhibition and Membrane Permeabilization of Candida lusitaniae Using Varied Pulse Shape Electroporation |
| Q38164120 | Hampered by historical paradigms--echinocandins and the treatment of Candida endocarditis |
| Q49679578 | In Vitro Antibiofilm Activity of Eucarobustol E against Candida albicans |
| Q42738793 | In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species |
| Q90676756 | In vitro activities of antifungals alone and in combination with tigecycline against Candida albicans biofilms |
| Q34590099 | In vitro activity of anidulafungin against Candida albicans biofilms |
| Q33451088 | In vitro antifungal activity of micafungin |
| Q35152853 | In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms |
| Q34024546 | Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents |
| Q38724208 | Management of Candida biofilms: state of knowledge and new options for prevention and eradication |
| Q44910278 | Micafungin plus fluconazole in an infected knee with retained hardware due to Candida albicans |
| Q41168995 | Micafungin triggers caspase-dependent apoptosis in Candida albicans and Candida parapsilosis biofilms, including caspofungin non-susceptible isolates. |
| Q38670904 | Novel strategies against Candida biofilms: interest of synthetic compounds |
| Q35406737 | Novel strategies to fight Candida species infection. |
| Q37242216 | Outcome of Candida Parapsilosis Complex Infections Treated with Caspofungin in Children |
| Q83480724 | Possible role of azole and echinocandin lock solutions in the control of Candida biofilms associated with silicone |
| Q34597683 | Quinacrine inhibits Candida albicans growth and filamentation at neutral pH. |
| Q26861656 | Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms |
| Q38633105 | Role of Echinocandins in Fungal Biofilm-Related Disease: Vascular Catheter-Related Infections, Immunomodulation, and Mucosal Surfaces |
| Q54631371 | Shunt lock therapy with micafungin to treat shunt-associated Candida albicans meningitis in an infant. |
| Q37026730 | Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates |
| Q42946675 | Susceptibility of Candida albicans biofilms to azithromycin, tigecycline and vancomycin and the interaction between tigecycline and antifungals |
| Q40920367 | Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production |
| Q35028539 | The effect of antifungal combination on transcripts of a subset of drug-resistance genes in clinical isolates of Candida species induced biofilms. |
| Q39619972 | The postantifungal and paradoxical effects of echinocandins against Candida spp. |
| Q35959489 | Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature |
| Q48544823 | What Could Be the Role of Antifungal Lock-Solutions? From Bench to Bedside |
| Q45942584 | [Potential of anidulafungin in hematological patients]. |
| Q51175640 | [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis]. |
Search more.